<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/42CFR110.html">Part 110
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  110.100  Injury Tables.
                            </h3>
                            <p class="depth1"><em>(a)</em> Pandemic influenza countermeasures injury table.
------------------------------------------------------------------------</p><p class="depth2">Time interval (for</p><p class="depth2">first symptom or</p><p class="depth2">manifestation of</p><p class="depth2">Covered countermeasures      Serious physical       onset of injury</p><p class="depth2">under Secretarial         injury (illness,    after administration</p><p class="depth2">declarations           disability, injury,    or use of covered</p><p class="depth2">or condition) \1\      countermeasure,</p><p class="depth2">unless otherwise</p><p class="depth2">specified)------------------------------------------------------------------------I. Pandemic influenza         A. Anaphylaxis......  A. 0-4 hours.</p><p class="depth2">vaccines administered by     B. Deltoid Bursitis.  B. 0-48 hours.</p><p class="depth2">needle into or through the   C. Vasovagal Syncope  C. 0-1 hour.</p><p class="depth2">skin.II. Pandemic influenza        A. Anaphylaxis......  A. 0-4 hours.</p><p class="depth2">intranasal vaccines.III. Pandemic influenza 2009  A. Guillain-          A. 3-42 days (not</p><p class="depth2">H1N1 vaccine.                 Barr[eacute]          less than 72 hours</p><p class="depth2">Syndrome.             and not more than</p><p class="depth2">42 days).IV. Oseltamivir Phosphate     A. Anaphylaxis......  A. 0-4 hours.</p><p class="depth2"><em>(Tamiflu)</em> when administered</p><p class="depth2">or used for pandemic</p><p class="depth2">influenza.V. Zanamivir (Relenza) when   A. Anaphylaxis......  A. 0-4 hours.</p><p class="depth2">administered or used for</p><p class="depth2">pandemic influenza.VI. Peramivir when            A. Anaphylaxis......  A. 0-4 hours.</p><p class="depth2">administered or used for</p><p class="depth2">2009 H1N1 influenza.</p><p class="depth2">VII. Pandemic influenza       A. No condition       A. Not applicable.</p><p class="depth2">personal respiratory          covered \2\.</p><p class="depth2">protection devices.VIII. Pandemic influenza      A. Postintubation     A. 2-42 days (not</p><p class="depth2">respiratory support devices.  Tracheal Stenosis.    less than 48 hours</p><p class="depth2">and not more than</p><p class="depth2">42 days) after</p><p class="depth2">extubation (removal</p><p class="depth2">of a tracheostomy</p><p class="depth2">or endotracheal</p><p class="depth2">tube).</p><p class="depth2">B. Ventilator-        B. More than 48</p><p class="depth2">Associated            hours after</p><p class="depth2">Pneumonia and         intubation</p><p class="depth2">Ventilator-           (placement of an</p><p class="depth2">Associated            endotracheal or</p><p class="depth2">Tracheobronchitis.    tracheostomy tube)</p><p class="depth2">and up to 48 hours</p><p class="depth2">after extubation</p><p class="depth2">(removal of the</p><p class="depth2">tube).</p><p class="depth2">C. Ventilator-        C. Throughout the</p><p class="depth2">Induced Lung Injury.  time of intubation</p><p class="depth2">(breathing through</p><p class="depth2">an endotracheal or</p><p class="depth2">tracheostomy tube)</p><p class="depth2">and up to 48 hours</p><p class="depth2">after extubation</p><p class="depth2">(removal of the</p><p class="depth2">tube).IX. Pandemic influenza        A. Bleeding Events..  A. Throughout the</p><p class="depth2">respiratory support device:                         time of</p><p class="depth2">Extra-corporeal membrane                            anticoagulation</p><p class="depth2">oxygenation (ECMO).                                 treatment for ECMO</p><p class="depth2">therapy, including</p><p class="depth2">the time needed to</p><p class="depth2">clear the effect of</p><p class="depth2">the anti-coagulant</p><p class="depth2">treatment from the</p><p class="depth2">body.X. Pandemic influenza         A. No condition       A. Not applicable.</p><p class="depth2">diagnostic testing devices.   covered.------------------------------------------------------------------------\1\ Serious physical injury as defined in 42 CFR 110.3(z). Only injuries</p><p class="depth2">that warranted hospitalization (whether or not the person was actually</p><p class="depth2">hospitalized) or injuries that led to a significant loss of function</p><p class="depth2">or disability will be considered serious physical injuries.\2\ The use of ``No condition covered'' in the Table reflects that the</p><p class="depth2">Secretary at this time does not find compelling, reliable, valid,</p><p class="depth2">medical and scientific evidence to support that any serious injury is</p><p class="depth2">presumed to be caused by the associated covered countermeasure. For</p><p class="depth2">injuries alleged to be due to covered countermeasures for which there</p><p class="depth2">is no associated Table injury, requesters must demonstrate that the</p><p class="depth2">injury occurred as the direct result of the administration or use of</p><p class="depth2">the covered countermeasure. See 42 CFR 110.20(b), (c).</p><p class="depth1"><em>(b)</em> Qualifications and aids to interpretation (table definitions and requirements). The following definitions and requirements shall apply to the Table set forth in this subpart and only apply for purposes of this subpart.</p><p class="depth2"><em>(1)</em> Anaphylaxis. Anaphylaxis is an acute, severe, and potentially lethal systemic reaction that occurs as a single discrete event with simultaneous involvement of two or more organ systems. Most cases resolve without sequelae. Signs and symptoms begin minutes to a few hours after exposure. Death, if it occurs, usually results from airway obstruction caused by laryngeal edema or bronchospasm and may be associated with cardiovascular collapse. Other significant clinical signs and symptoms may include the following: Cyanosis, hypotension, bradycardia, tachycardia, arrhythmia, edema of the pharynx and/or trachea and/or larynx with stridor and dyspnea. There are no specific pathological findings to confirm a diagnosis of anaphylaxis.</p><p class="depth2"><em>(2)</em> Deltoid bursitis. Deltoid bursitis is an inflammation of the bursa that lies beneath the deltoid muscle and between the acromion process and the rotator cuff. Subdeltoid bursitis manifests with pain in the lateral aspect of the shoulder similar to rotator cuff tendonitis. The presence of tenderness on direct palpation beneath the acromion process distinguishes this bursitis from rotator cuff tendonitis. Similar to tendonitis, isolated bursitis will have full passive range of motion. Other causes of bursitis such as trauma (other than from vaccination), metabolic disorders, and systemic diseases such as rheumatoid arthritis, dialysis, and infection will not be considered Table injuries. This list is not exhaustive. The deltoid bursitis must occur in the same shoulder that received the pandemic influenza vaccine.</p><p class="depth2"><em>(3)</em> Vasovagal syncope. Vasovagal syncope (also sometimes called neurocardiogenic syncope) means loss of consciousness (fainting) and loss of postural tone caused by a transient decrease in blood flow to the brain occurring after the administration of an injected countermeasure. Vasovagal syncope is usually a benign condition but may result in falling and injury with significant sequelae. Vasovagal syncope may be preceded by symptoms such as

nausea, lightheadedness, diaphoresis, and/or pallor. Vasovagal syncope may be associated with transient seizure-like activity, but recovery of orientation and consciousness generally occurs simultaneously. Loss of consciousness resulting from the following conditions will not be considered vasovagal syncope: Organic heart disease; cardiac arrhythmias; transient ischemic attacks; hyperventilation; metabolic conditions; neurological conditions; psychiatric conditions; seizures; trauma; and situational as can occur with urination, defecation, or cough. This list is not complete. Episodes of recurrent syncope occurring after the applicable time period are not considered to be sequelae of an episode of syncope meeting the Table requirements.</p><p class="depth2"><em>(4)</em> Guillain-Barr[eacute] Syndrome (GBS). (i) GBS is an acute monophasic peripheral neuropathy that currently is known to encompass a spectrum of four clinicopathological subtypes described below. For each subtype of GBS, the interval between the first appearance of symptoms and the nadir of weakness is between 12 hours and 28 days. This is followed in all subtypes by a clinical plateau with stabilization at the nadir of symptoms, or subsequent improvement without significant relapse. Death may occur without a clinical plateau. Treatment related fluctuations in all subtypes of GBS can occur within 9 weeks of GBS symptom onset and recurrence of symptoms after this time frame would not be consistent with GBS.</p><p class="depth3"><em>(i)</em> GBS is an acute monophasic peripheral neuropathy that currently is known to encompass a spectrum of four clinicopathological subtypes described below. For each subtype of GBS, the interval between the first appearance of symptoms and the nadir of weakness is between 12 hours and 28 days. This is followed in all subtypes by a clinical plateau with stabilization at the nadir of symptoms, or subsequent improvement without significant relapse. Death may occur without a clinical plateau. Treatment related fluctuations in all subtypes of GBS can occur within 9 weeks of GBS symptom onset and recurrence of symptoms after this time frame would not be consistent with GBS.</p><p class="depth3"><em>(ii)</em> The most common subtype in North America and Europe, comprising more than 90 percent of cases, is acute inflammatory demyelinating polyneuropathy (AIDP) which has the pathologic and electrodiagnostic features of focal demyelination of motor and sensory peripheral nerves and nerve roots. Another subtype called acute motor axonal neuropathy (AMAN) is generally seen in other parts of the world and is predominated by axonal damage that primarily affects motor nerves. AMAN lacks features of demyelination. Another less common subtype of GBS includes acute motor and sensory neuropathy (AMSAN), which is an axonal form of GBS that is similar to AMAN, but also affects the sensory nerves and roots. AIDP, AMAN, and AMSAN are typically characterized by symmetric motor flaccid weakness, sensory abnormalities, and/or autonomic dysfunction caused by autoimmune damage to peripheral nerves and nerve roots. The diagnosis of AIDP, AMAN, and AMSAN requires bilateral flaccid limb weakness and decreased or absent deep tendon reflexes in weak limbs; a monophasic illness pattern; an interval between onset and nadir of weakness between 12 hours and 28 days; subsequent clinical plateau (the clinical plateau leads to either stabilization at the nadir of symptoms, or subsequent improvement without significant relapse); and, the absence of an identified more likely alternative diagnosis. Death may occur without a clinical plateau.</p><p class="depth3"><em>(iii)</em> Fisher syndrome (FS), also known as Miller-Fisher Syndrome, is a subtype of GBS characterized by ataxia, areflexia, and ophthalmoplegia, and overlap between FS and AIDP may be seen with limb weakness. The diagnosis of FS requires bilateral ophthalmoparesis; bilateral reduced or absent tendon reflexes; ataxia; the absence of limb weakness (the presence of limb weakness suggests a diagnosis of AIDP); a monophasic illness pattern; an interval between onset and nadir of weakness between 12 hours and 28 days; subsequent clinical plateau (the clinical plateau leads to either stabilization at the nadir of symptoms, or subsequent improvement without significant relapse); no alteration in consciousness; no corticospinal track signs; and, the absence of an identified more likely alternative diagnosis. Death may occur without a clinical plateau.</p><p class="depth3"><em>(iv)</em> Evidence that is supportive, but not required, of a diagnosis of all subtypes of GBS includes electrophysiologic findings consistent with GBS or an elevation of cerebral spinal fluid (CSF) protein with a total CSF white blood cell count below 50 cells per microliter. The results of both CSF and electrophysiologic studies are frequently normal in the first week of illness in otherwise typical cases of GBS.</p><p class="depth3"><em>(v)</em> For GBS to qualify as a Table injury there must not be a more likely alternative diagnosis for the weakness. Exclusionary criteria for the diagnosis of all subtypes of GBS include the ultimate diagnosis of any of the following conditions: Chronic immune demyelinating polyradiculopathy (``CIDP''), carcinomatous meningitis, brain stem encephalitis (other than Bickerstaff brainstem encephalitis), myelitis, spinal cord infarct, spinal cord compression, anterior horn cell diseases such as polio or West Nile virus infection, subacute inflammatory demyelinating polyradiculoneuropathy, multiple sclerosis, cauda equina compression, metabolic conditions such as hypermagnesemia or hypophosphatemia, tick paralysis, heavy metal toxicity (such as arsenic, gold, or thallium), drug-induced neuropathy (such as vincristine, platinum compounds, or nitrofurantoin), porphyria, critical illness neuropathy, vasculitis, diphtheria, myasthenia gravis, organophosphate poisoning, botulism, critical illness myopathy, polymyositis, dermatomyositis, hypokalemia, or hyperkalemia. The above list is not exhaustive.</p><p class="depth2"><em>(5)</em> Tracheal stenosis. (i) Postintubation tracheal stenosis means an iatrogenic (caused by medical treatment) and symptomatic stricture of the airway (narrowing of the windpipe) resulting from:</p><p class="depth3"><em>(i)</em> Postintubation tracheal stenosis means an iatrogenic (caused by medical treatment) and symptomatic stricture of the airway (narrowing of the windpipe) resulting from:</p><p class="depth4"><em>(A)</em> Trauma or necrosis from an endotracheal tube; or</p><p class="depth4"><em>(B)</em> Stomal injury from a tracheostomy; or</p><p class="depth4"><em>(C)</em> A combination of the two.</p><p class="depth3"><em>(ii)</em> Tracheal stenosis or narrowing due to tumors (malignant or benign), infections of the trachea (such as tuberculosis, fungal diseases), radiotherapy, tracheal surgery, trauma, congenital, and inflammatory or autoimmune diseases will not be considered post-intubation tracheal stenosis. Post-intubation tracheal stenosis requires either tracheostomy with placement of a tracheostomy tube or endotracheal intubation. Diagnosis requires symptoms of upper airway obstruction such as stridor (inspiratory wheeze) or exertional dyspnea (increased shortness of breath with exertion), and positive radiologic studies showing abnormal narrowing of the trachea or bronchoscopic evaluation that demonstrates abnormal narrowing.</p><p class="depth2"><em>(6)</em> Ventilator-Associated Pneumonia (VAP) and Ventilator-Associated Tracheobronchitis (VAT). (i) VAP is defined as an iatrogenic pneumonia caused by the medical treatment of mechanical ventilation. Similarly, VAT is an iatrogenic infection of the trachea and/or bronchi caused by mechanical ventilation. The initial manifestation of VAP and VAT must occur more than 48 hours after intubation (placement of the breathing tube) and up to 48 hours after extubation (removal of the breathing tube). VAP will be considered to be present when the patient demonstrates a new or progressive radiographic infiltrate that is in the lungs and consistent with pneumonia, fever, leukocytosis (increased white blood cell count) or leucopenia (decreased white blood cell count), purulent (containing pus) tracheal secretions from a tracheal aspirate, and a positive lower respiratory tract culture. The positive lower respiratory tract culture is a diagnostic requirement only if there has not been a change in antibiotics in the 72 hours prior to collection of the culture. In addition, a tracheal aspirate that does not demonstrate bacteria or inflammatory cells in a patient without a change in antibiotics in the previous 72 hours is unlikely to be VAP and shall not be considered a condition set forth in the Table.</p><p class="depth3"><em>(i)</em> VAP is defined as an iatrogenic pneumonia caused by the medical treatment of mechanical ventilation. Similarly, VAT is an iatrogenic infection of the trachea and/or bronchi caused by mechanical ventilation. The initial manifestation of VAP and VAT must occur more than 48 hours after intubation (placement of the breathing tube) and up to 48 hours after extubation (removal of the breathing tube). VAP will be considered to be present when the patient demonstrates a new or progressive radiographic infiltrate that is in the lungs and consistent with pneumonia, fever, leukocytosis (increased white blood cell count) or leucopenia (decreased white blood cell count), purulent (containing pus) tracheal secretions from a tracheal aspirate, and a positive lower respiratory tract culture. The positive lower respiratory tract culture is a diagnostic requirement only if there has not been a change in antibiotics in the 72 hours prior to collection of the culture. In addition, a tracheal aspirate that does not demonstrate bacteria or inflammatory cells in a patient without a change in antibiotics in the previous 72 hours is unlikely to be VAP and shall not be considered a condition set forth in the Table.</p><p class="depth3"><em>(ii)</em> VAT will be considered to be present when the patient demonstrates fever, leukocytosis or leukopenia, purulent tracheal secretions, and a positive tracheal aspirate culture in the absence of a change of antibiotics within the 72 hours prior to culture. Tracheal colonization with microorganisms is common in intubated patients, but in the absence of clinical findings is not a sign of VAT.</p><p class="depth2"><em>(7)</em> Ventilator-Induced Lung Injury (VILI). VILI results from mechanical trauma such as volutrauma leading to rupture of alveoli (air sacs in the lungs where oxygen and carbon dioxide are exchanged with the blood) with subsequent abnormal leakage of air. VILI manifests as iatrogenic pneumothorax

(abnormal air from alveolar rupture in the pleural space), pneumomediastinum (abnormal air from alveolar rupture in the mediastinum (middle part of the chest between the lungs)), pulmonary interstitial emphysema (abnormal air in the lung interstitial space between the alveoli), subpleural air cysts (an extreme form of pulmonary emphysema where the abnormal air in the interstitial space has pooled into larger pockets), subcutaneous emphysema (abnormal air from alveolar rupture that has dissected into the skin), pneumopericardium (abnormal air from alveolar rupture that has traveled to the pericardium (covering of the heart)), pneumoperitoneum (abnormal air from alveolar rupture that has moved into the abdominal space), or systemic air embolism (abnormal air from alveolar rupture that has moved into the blood). To qualify as Table injuries, these manifestations must occur in patients who are being mechanically ventilated at the time of initial manifestation of the VILI.</p><p class="depth2"><em>(8)</em> Bleeding events. Bleeding events are defined as excessive or abnormal bleeding in patients who are under the pharmacologic effects of anticoagulant therapy provided for extracorporeal membrane oxygenation (ECMO) treatment.</p><p class="depth1"><em>(c)</em> Covered countermeasures. The Office of the Secretary publishes Secretarial declarations on the following covered countermeasures in the Federal Register:</p><p class="depth2"><em>(1)</em> Pandemic influenza vaccines;</p><p class="depth2"><em>(2)</em> Tamiflu;</p><p class="depth2"><em>(3)</em> Relenza;</p><p class="depth2"><em>(4)</em> Peramivir;</p><p class="depth2"><em>(5)</em> Personal respiratory protection devices;</p><p class="depth2"><em>(6)</em> Respiratory support devices;</p><p class="depth2"><em>(7)</em> Diagnostic testing devices.
[80 FR 47416, Aug. 7, 2015]</p><p class="depth3">SUBCHAPTER K_HEALTH RESOURCES DEVELOPMENT</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
